Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Renslow Sherer, MD, discusses key data on COVID-19 oral antiviral agents—molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir—for nonhospitalized adults with mild to moderate COVID-19, including:
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
This program has been made available online.
Clinical Care Options (CCO) module with insights from Dr. Michael Ison on SARS-CoV-2 antivirals and monoclonal antibodies for outpatient treatment
Download slides reviewing the latest data and guidance on COVID-19 vaccinations, including authorized and investigational agents, from Clinical Care Options (CCO)
Prof Sharon R. Lewin on treatments for nonhospitalized patients with COVID-19, remdesivir updates, and ivermectin data, from Clinical Care Options (CCO)
Prof Cristina Mussini discusses new data from ECCMID 2022 on COVID-19 treatments, vaccination, and long COVID, from Clinical Care Options (CCO)